Entrectinib, the kinase inhibitor drug initially discovered and developed by Nerviano Medical Sciences approved by AIFA in two oncology indications
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency AIFA in two oncology indications: lung cancer ROS1 kinase fusion positive, and any solid […]
CPhI Worldwide
Where: Fiera Milano, Milan, Italy When: 9 November – 11 November 2021 CPhI Worldwide 2021 has established itself as the flagship event for the pharmaceutical industry. The upcoming edition of the expo will be staged from 9th to 11th of November at Fiera Milano. The organizers expect an even bigger gathering of professionals and […]
Accelera and BiomimX: Commercial agreement
Nerviano, 30 June 2021 Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process. The commercial agreement between the Companies determines that Accelera proposes within its commercial offer BiomimX®’s technological solutions: uHeart and uKnee. uHeart, is […]
The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene
Fugazza C, Barbarani G, Elangovan S, Marini MG, Giolitto S, Font-Monclus I, Marongiu MF, Manunza L, Strouboulis J, Cantù C, Gasparri F, Barabino SML, Nakamura Y, Ottolenghi S, Moi P, Ronchi AE Haematologica (2021), 106(2), 474-482
RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis
La Ferlita A, Alaimo S, Di Bella S, Martorana E, Laliotis G, Bertoni F, Cascione L, Tsichlis P, Ferro A, Bosotti R, Pulvirenti A BMC Bioinformatics (2021), volume 22, Article number: 298
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S, Sala GL Pharmaceutics (2021), 13(4), 483
Identification of unprecedented ATP-competitive choline kinase inhibitors
Quartieri F, Nesi M, Avanzi N, Borghi D, Casale E, Corti E, Cucchi U, Donati D, Fasolini M, Felder E, Galvani A, Giorgini ML, Lomolino A, Menichincheri M, Orrenius C, Perrera C, Re Depaolini S, Riccardi-Sirtori F, Salsi E, Isacchi A, Gnocchi P Bioorg Med Chem Lett (2021), 51, 128310
NMS Group wins China Awards for creating concrete values
Nerviano, 9 February 2021 NMS Group has been named the winner of the “Value creators’ category at the prestigious ‘China Awards 2021′ during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value creators’ award is a recognition for companies in Italy that have successfully implemented concrete projects aiming […]
A benchmarking of pipelines for detecting ncRNAs from RNA-Seq data
Di Bella S, La Ferlita A, Carapezza G, Alaimo S, Isacchi A, Ferro A, Pulvirenti A, Bosotti R Brief Bioinform (2019), Nov 18 [Epub ahead of print]
Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database
Somaschini A, Di Bella S, Cusi C, Raddrizzani L, Leone A, Carapezza G, Mazza T, Isacchi A, Bosotti R Sci Data. 2020 Nov 30;7(1):420. doi: 10.1038/s41597-020-00761-2. PMID: 33257674; PMCID: PMC7705673.